Results from bendamustine-based combinations. Progression-free survival by induction regimen (A) or maintenance regimen (B) in the Smith et al1 randomized trial. B, bendamustine; CI, confidence interval; HR, hazard ratio; LR, lenalidomide, rituximab; V, bortezomib (Velcade); R, rituximab; L, lenalidomide. See Figure 2A-B in the article by Smith et al1 beginning on page 1083.
